Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 12/20 | 0.42 |
| ▸ | MPC2 | O95563 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394084 | 0.92 | FFAR1 (0.52) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL6182666 | 0.90 | FFAR1 (0.52) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL5383043 | 0.88 | FFAR1 (0.46) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL6184382 | 0.88 | FFAR1 (0.48) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL5407319 | 0.88 | FFAR1 (0.52) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL6188185 | 0.88 | MAPT (0.51) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL6184045 | 0.86 | FFAR1 (0.54) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL5388747 | 0.86 | FFAR1 (0.66) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL6185615 | 0.85 | FFAR1 (0.53) | FFAR1PPARGMPC2CYP2C8CYP2C9 | |
| SCHEMBL5386762 | 0.85 | FFAR1 (0.43) | FFAR1PPARGMPC2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458697-B1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RES & DEV (FR) | 2006-09-06 | — | — | EP | claimed |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. | 2005-06-23 | — | — | US | claimed |
| US-6908939-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-06-21 | — | — | US | claimed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | claimed |
| US-7294639-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-7122564-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-17 | — | — | US | disclosed |
| EP-1458697-B1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RES & DEV (FR) | 2006-09-06 | — | — | EP | disclosed |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. | 2005-06-23 | — | — | US | disclosed |
| US-6908939-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-06-21 | — | — | US | disclosed |
| EP-1458697-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | Galderma Research & Development, S.N.C. (FR) | 2004-09-22 | — | — | EP | disclosed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| WO-2003055867-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | PPARG, PPARA, PPARD | FFAR1 13/4885PPARG 1/4885MPC2 2469/4885 |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | FFAR1 13/4885PPARG 1/4885MPC2 2469/4885 |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | FFAR1 10/4885PPARG 1/4885MPC2 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.